Garland Jason K
Known title: CFOCIK: 0001754555
Associated companies
Transaction History
| RGEN | ▼ Sell | Tax Withholding | 421 | $80K | 9/25/2026 | View on chart |
| RGEN | ▼ Sell | Open Market | 530 | $80K | 7/16/2026 | View on chart |
| RGEN | ▼ Sell | Open Market | 733 | $106K | 6/25/2026 | View on chart |
| RGEN | ▲ Buy | Grant | 7,751 | $0 | 3/5/2026 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 715 | $89K | 3/2/2026 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 327 | $42K | 2/27/2026 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 412 | $50K | 9/25/2025 | View on chart |
| RGEN | ▲ Buy | Grant | 6,435 | $0 | 3/3/2025 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 316 | $49K | 2/27/2025 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 367 | $45K | 11/20/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 2,540 | $0 | 2/27/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 5,503 | $0 | 9/25/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.